Literature DB >> 31820000

European Society of Cardiology: Cardiovascular Disease Statistics 2019.

Adam Timmis1, Nick Townsend2, Chris P Gale3, Aleksandra Torbica4, Maddalena Lettino5, Steffen E Petersen1, Elias A Mossialos6, Aldo P Maggioni7, Dzianis Kazakiewicz8, Heidi T May9, Delphine De Smedt10, Marcus Flather11, Liesl Zuhlke12, John F Beltrame13, Radu Huculeci8, Luigi Tavazzi14, Gerhard Hindricks15, Jeroen Bax16, Barbara Casadei17, Stephan Achenbach18, Lucy Wright19, Panos Vardas8.   

Abstract

AIMS: The 2019 report from the European Society of Cardiology (ESC) Atlas provides a contemporary analysis of cardiovascular disease (CVD) statistics across 56 member countries, with particular emphasis on international inequalities in disease burden and healthcare delivery together with estimates of progress towards meeting 2025 World Health Organization (WHO) non-communicable disease targets. METHODS AND
RESULTS: In this report, contemporary CVD statistics are presented for member countries of the ESC. The statistics are drawn from the ESC Atlas which is a repository of CVD data from a variety of sources including the WHO, the Institute for Health Metrics and Evaluation, and the World Bank. The Atlas also includes novel ESC sponsored data on human and capital infrastructure and cardiovascular healthcare delivery obtained by annual survey of the national societies of ESC member countries. Across ESC member countries, the prevalence of obesity (body mass index ≥30 kg/m2) and diabetes has increased two- to three-fold during the last 30 years making the WHO 2025 target to halt rises in these risk factors unlikely to be achieved. More encouraging have been variable declines in hypertension, smoking, and alcohol consumption but on current trends only the reduction in smoking from 28% to 21% during the last 20 years appears sufficient for the WHO target to be achieved. The median age-standardized prevalence of major risk factors was higher in middle-income compared with high-income ESC member countries for hypertension {23.8% [interquartile range (IQR) 22.5-23.1%] vs. 15.7% (IQR 14.5-21.1%)}, diabetes [7.7% (IQR 7.1-10.1%) vs. 5.6% (IQR 4.8-7.0%)], and among males smoking [43.8% (IQR 37.4-48.0%) vs. 26.0% (IQR 20.9-31.7%)] although among females smoking was less common in middle-income countries [8.7% (IQR 3.0-10.8) vs. 16.7% (IQR 13.9-19.7%)]. There were associated inequalities in disease burden with disability-adjusted life years per 100 000 people due to CVD over three times as high in middle-income [7160 (IQR 5655-8115)] compared with high-income [2235 (IQR 1896-3602)] countries. Cardiovascular disease mortality was also higher in middle-income countries where it accounted for a greater proportion of potential years of life lost compared with high-income countries in both females (43% vs. 28%) and males (39% vs. 28%). Despite the inequalities in disease burden across ESC member countries, survey data from the National Cardiac Societies of the ESC showed that middle-income member countries remain severely under-resourced compared with high-income countries in terms of cardiological person-power and technological infrastructure. Under-resourcing in middle-income countries is associated with a severe procedural deficit compared with high-income countries in terms of coronary intervention, device implantation and cardiac surgical procedures.
CONCLUSION: A seemingly inexorable rise in the prevalence of obesity and diabetes currently provides the greatest challenge to achieving further reductions in CVD burden across ESC member countries. Additional challenges are provided by inequalities in disease burden that now require intensification of policy initiatives in order to reduce population risk and prioritize cardiovascular healthcare delivery, particularly in the middle-income countries of the ESC where need is greatest. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Cardiovascular disease; European Society of Cardiology; Health infrastructure; Morbidity; Mortality; Risk factors; Service provision; Statistics

Mesh:

Year:  2020        PMID: 31820000     DOI: 10.1093/eurheartj/ehz859

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  163 in total

1.  Effects of Three-Month Feeding High Fat Diets with Different Fatty Acid Composition on Myocardial Proteome in Mice.

Authors:  Adam Lepczyński; Małgorzata Ożgo; Katarzyna Michałek; Alicja Dratwa-Chałupnik; Marta Grabowska; Agnieszka Herosimczyk; Kamila P Liput; Ewa Poławska; Andrzej Kram; Mariusz Pierzchała
Journal:  Nutrients       Date:  2021-01-23       Impact factor: 5.717

2.  Protein Intake and Physical Activity in Newly Diagnosed Patients with Acute Coronary Syndrome: A 5-Year Longitudinal Study.

Authors:  Andrea Greco; Agostino Brugnera; Roberta Adorni; Marco D'Addario; Francesco Fattirolli; Cristina Franzelli; Cristina Giannattasio; Alessandro Maloberti; Francesco Zanatta; Patrizia Steca
Journal:  Nutrients       Date:  2021-02-16       Impact factor: 5.717

Review 3.  Personalized medicine for cardiovascular diseases.

Authors:  Hayato Tada; Noboru Fujino; Akihiro Nomura; Chiaki Nakanishi; Kenshi Hayashi; Masayuki Takamura; Masa-Aki Kawashiri
Journal:  J Hum Genet       Date:  2020-08-08       Impact factor: 3.172

4.  European Society of Cardiology methodology for the development of quality indicators for the quantification of cardiovascular care and outcomes.

Authors:  Suleman Aktaa; Gorav Batra; Lars Wallentin; Colin Baigent; David Erlinge; Stefan James; Peter Ludman; Aldo P Maggioni; Susanna Price; Clive Weston; Barbara Casadei; Chris P Gale
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2022-01-05

5.  Melatonin and Cardioprotection in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Alberto Domínguez-Rodríguez; Pedro Abreu-González; Néstor Báez-Ferrer; Russel J Reiter; Pablo Avanzas; Daniel Hernández-Vaquero
Journal:  Front Cardiovasc Med       Date:  2021-05-12

6.  Effects of Probiotics on Patients with Hypertension: a Systematic Review and Meta-Analysis.

Authors:  Cheng Chi; Cheng Li; Dongjun Wu; Nicholas Buys; Wenjun Wang; Huimin Fan; Jing Sun
Journal:  Curr Hypertens Rep       Date:  2020-03-21       Impact factor: 5.369

7.  Late-life voluntary wheel running reverses age-related aortic stiffness in mice: a translational model for studying mechanisms of exercise-mediated arterial de-stiffening.

Authors:  Rachel A Gioscia-Ryan; Zachary S Clayton; Bradley S Fleenor; Jason S Eng; Lawrence C Johnson; Matthew J Rossman; Melanie C Zigler; Trent D Evans; Douglas R Seals
Journal:  Geroscience       Date:  2020-06-11       Impact factor: 7.713

8.  Patient-reported outcomes, sociodemographic and clinical factors are associated with 1-year mortality in patients with ischemic heart disease-findings from the DenHeart cohort study.

Authors:  Trine Bernholdt Rasmussen; Britt Borregaard; Pernille Palm; Rikke Elmose Mols; Anne Vinggaard Christensen; Knud Juel; Ola Ekholm; Charlotte Brun Thorup; Lars Thrysoee; Marie Gjengedal; Selina Kikkenborg Berg
Journal:  Qual Life Res       Date:  2021-07-22       Impact factor: 4.147

9.  BRD4 (Bromodomain-Containing Protein 4) Interacts with GATA4 (GATA Binding Protein 4) to Govern Mitochondrial Homeostasis in Adult Cardiomyocytes.

Authors:  Arun Padmanabhan; Michael Alexanian; Ricardo Linares-Saldana; Rajan Jain; Deepak Srivastava; Bárbara González-Terán; Gaia Andreoletti; Yu Huang; Andrew J Connolly; Wonho Kim; Austin Hsu; Qiming Duan; Sarah A B Winchester; Franco Felix; Juan A Perez-Bermejo; Qiaohong Wang; Li Li; Parisha P Shah; Saptarsi M Haldar
Journal:  Circulation       Date:  2020-10-23       Impact factor: 29.690

10.  Lifelong voluntary aerobic exercise prevents age- and Western diet- induced vascular dysfunction, mitochondrial oxidative stress and inflammation in mice.

Authors:  Rachel A Gioscia-Ryan; Zachary S Clayton; Melanie C Zigler; James J Richey; Lauren M Cuevas; Matthew J Rossman; Micah L Battson; Brian P Ziemba; David A Hutton; Nicholas S VanDongen; Douglas R Seals
Journal:  J Physiol       Date:  2020-10-28       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.